ClinicalTrials.gg
CompletedNCT01716585Updated Jul 12, 2021Results posted

A Study to Evaluate Chronic Hepatitis C Infection

A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin in Chronic Hepatitis C Infection, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-12.

Primary conditionHepatitis C, ChronicRegistry: Hepatitis CReclassifiedWhy we changed it
Registry
Hepatitis C — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis C, Chronic
Why
  1. The study's listed conditions name Hepatitis C, Chronic, a narrower term within Hepatitis C.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing paritaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. paritaprevir · Hepatitis C, Chronic.

Enrollment
2nd of 16
636 · median 124
Started
2012
with 3 others
Phase 3
9 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
4 of 16
AbbVie (prior sponsor, Abbott)

Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, this one is the 2nd largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 4th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 16 studies testing paritaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

About paritaprevir

paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing paritaprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV) in hepatitis C virus genotype 1 infected treatment-naïve adults.

03

Conditions studied

  • Chronic Hepatitis C Infection

Browse trials for

Keywords

  • Hepatitis C Virus
  • Hepatitis C Genotype 1
  • Hepatitis C
  • Treatment-Naïve
  • Interferon-Free
  • Chronic Hepatitis C
  • Viekira Pak
  • ombitasvir
  • paritaprevir
  • dasabuvir
04

In context

Hepatitis C, Chronic Reclassified

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

This study's enrollment of 636 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.

Browse Hepatitis C, Chronic studies →

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Compared within Hepatitis C, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis C. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be for at least 2 years or surgically sterile or practicing specific forms of
  • Chronic , genotype 1-infection and HCV RNA level greater than 10,000 IU/mL at screening
  • Subject has never received antiviral treatment for hepatitis C infection
  • No evidence of liver cirrhosis

Exclusion criteria

Exclusion Criteria:

  • Positive screen for drugs or alcohol
  • Significant sensitivity to any drug
  • Use of medications within 2 weeks of dosing
  • Certain predefined abnormal laboratory tests
  • Positive surface antigen or anti- antibody
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
636 participants (actual)

Study arms

  • Experimental
    ABT-450/r/ABT-267 and ABT-333, plus RBV

    Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin

  • Experimental
    Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV

    Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin · Drug: Placebo for ABT-450/r/ABT-267 · Drug: Placebo for ABT-333 · Drug: Placebo for ribavirin

Interventions

  • DrugABT-450/r/ABT-267, ABT-333

    Drug pages: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir

    ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

    Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK

  • Capsule (double-blind treatment period), tablet (open-label treatment period)

  • DrugPlacebo for ABT-450/r/ABT-267

    Tablet

  • DrugPlacebo for ABT-333

    Tablet

  • DrugPlacebo for ribavirin

    Capsule

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of active study drug

Secondary outcomes

  1. Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period

    Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline.

    Time frame: At 12 weeks

  2. Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of active study drug

  3. Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of active study drug

  4. Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm

    Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid \[HCV RNA\] ≥ lower limit of quantification \[LLOQ\] after HCV RNA \< LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment.

    Time frame: 12 weeks after the last actual dose of active study drug

  5. Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm

    Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.

    Time frame: Within 12 weeks post-treatment

08

Results

Posted Jan 6, 2015

Participant flow

Double-blind Treatment
Participant flow — Double-blind Treatment
MilestoneABT-450/r/ABT-267 and ABT-333, Plus RBVPlacebo Followed by ABT-450/r/ABT-267 and ABT-333, Plus RBV
Started477159
Randomized but not treated41
Completed464157
Not completed132
Withdrew: Did not receive study drug41
Withdrew: Adverse event21
Withdrew: Withdrawal by subject30
Withdrew: Lost to follow-up20
Withdrew: Subject noncompliant10
Withdrew: Other10
Open-label Treatment
Participant flow — Open-label Treatment
MilestoneABT-450/r/ABT-267 and ABT-333, Plus RBVPlacebo Followed by ABT-450/r/ABT-267 and ABT-333, Plus RBV
Started0157
Completed0150
Not completed07
Withdrew: Adverse event02
Withdrew: Virologic failure02
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Treatment

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment96.4
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV · Percentage of participants with svr12: 96.4 · 95% CI 94.7 to 98.1In order to control the Type I error rate at 0.05, a fixed-sequence testing procedure was used to proceed through the primary and first 3 secondary efficacy endpoints in the order numbered below.
SecondaryPercentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period

Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline.

Time frame:
At 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBVPlacebo
Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period97.015.8
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV vs Placebo · Fisher Exact · p = < 0.001 (In order to control the Type I error rate at 0.05, a fixed-sequence testing procedure will be used to proceed through the primary and first 3 secondary efficacy endpoints in the order numbered below.)
SecondaryPercentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV
Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment95.7
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV · Percentage of participants with svr12: 95.7 · 95% CI 93.4 to 97.995% CI calculated using the normal approximation to the binomial distribution.
SecondaryPercentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV
Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment98.0 (95.8 to 100.0)
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV · Percentage of participants with svr12: 98.0 · 95% CI 95.8 to 100.095% CI calculated using the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm

Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid \[HCV RNA\] ≥ lower limit of quantification \[LLOQ\] after HCV RNA \< LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment.

Time frame:
12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV
Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm0.2 (0.0 to 0.6)
SecondaryPercentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm

Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.

Time frame:
Within 12 weeks post-treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV
Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm1.5 (0.4 to 2.6)

Adverse events

Collected over Adverse events (AEs) were collected from the start of active study drug administration (double-blind [DB]/open-label, OL active) to 30 days after the last dose of active study drug 16 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind ABT-450/r/ABT-267 and ABT-333, Plus RBV—10/473 (2.1%)391/473 (82.7%)
Double Blind Placebo—0/158 (0%)108/158 (68.4%)
Open Label ABT-450/r/ABT-267 and ABT-333, Plus RBV—2/157 (1.3%)117/157 (74.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventDouble Blind ABT-450/r/ABT-267 and ABT-333, Plus RBVDouble Blind PlaceboOpen Label ABT-450/r/ABT-267 and ABT-333, Plus RBV
BILIARY COLICHepatobiliary disorders0/4730/1581/157
SUBCUTANEOUS ABSCESSInfections and infestations0/4730/1581/157
ANAEMIABlood and lymphatic system disorders1/4730/1580/157
SINUS TACHYCARDIACardiac disorders1/4730/1580/157
VENTRICULAR EXTRASYSTOLESCardiac disorders1/4730/1580/157
ABDOMINAL PAINGastrointestinal disorders1/4730/1580/157
DIARRHOEAGastrointestinal disorders1/4730/1580/157
NAUSEAGastrointestinal disorders1/4730/1580/157
VOMITINGGastrointestinal disorders1/4730/1580/157
CHILLSGeneral disorders1/4730/1580/157
Most frequent other events
Showing 10 of 27
Most frequent other events
EventDouble Blind ABT-450/r/ABT-267 and ABT-333, Plus RBVDouble Blind PlaceboOpen Label ABT-450/r/ABT-267 and ABT-333, Plus RBV
FATIGUEGeneral disorders164/47345/15835/157
HEADACHENervous system disorders156/47342/15826/157
NAUSEAGastrointestinal disorders112/47322/15824/157
PRURITUSSkin and subcutaneous tissue disorders80/4737/15816/157
INSOMNIAPsychiatric disorders67/47312/15821/157
DIARRHOEAGastrointestinal disorders65/47311/15819/157
ASTHENIAGeneral disorders59/4736/15810/157
RASHSkin and subcutaneous tissue disorders51/4739/1588/157
ANAEMIABlood and lymphatic system disorders24/4730/15814/157
DIZZINESSNervous system disorders38/4736/1585/157

Baseline characteristics

Safety population: all randomized participants who received at least 1 dose of blinded study drug

Age, Continuous
Age, Continuous(years)ABT-450/r/ABT-267 and ABT-333, Plus RBVPlaceboTotal
Mean49.4 ± 10.9851.2 ± 10.2349.9 ± 10.82
Sex: Female, Male
Sex: Female, Male(Participants)ABT-450/r/ABT-267 and ABT-333, Plus RBVPlaceboTotal
Female20285287
Male27173344
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10. PubMed 24720703 ↗
  • Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int. 2018 Sep;38(9):1571-1575. doi: 10.1111/liv.13708. Epub 2018 Mar 14. PubMed 29377566 ↗
  • Cloherty G, Chevaliez S, Sarrazin C, Herman C, Holzmayer V, Dawson G, Maasoumy B, Vermehren J, Wedemeyer H, Feld JJ, Pawlotsky JM. Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. Sci Rep. 2016 Oct 20;6:35410. doi: 10.1038/srep35410. PubMed 27762283 ↗
  • Chevaliez S, Feld J, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, Herman C, Hackett J, Cohen D, Dawson G, Pawlotsky JM, Cloherty G. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther. 2018;23(3):211-217. doi: 10.3851/IMP3042. PubMed 27115431 ↗

Related links

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Oct 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2012
First posted
Oct 30, 2012
Start
Nov 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2014
Results first posted
Jan 6, 2015
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01716585
Responsible party
Sponsor
First posted
Oct 30, 2012
Start date
Nov 2012
Primary completion
Oct 2013
Completion
Oct 2014
Results posted
Jan 6, 2015
Last update
Jul 12, 2021

Study contacts

Nancy Shulman, MD
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir · Ribavirin

Start the discussion